Clover Announces U.S. IND Clearance and Initiation of Revaccination Clinical Study for RSV Vaccine Candidate SCB-1019
March 24, 2025 | 06:56
Clover Biopharmaceuticals, Ltd.today announced IND clearance by U.S. FDA and that enrollment of the first participants has been completed in a Phase I revaccination clinical trial evaluating SCB-1019
Clover announces positive clinical data for RSV Vaccine candidate SCB-1019 compared head-to-Head Versus GSK's AREXVY
October 29, 2024 | 05:32
Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world..
Mobile Version